MTPS9579A

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

AsthmaChronic Spontaneous Urticaria

Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller

CompletedNCT04092582

Genentech, Inc.Asthma

Start: 2019-10-31End: 2022-05-19Updated: 2023-08-14

A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria

WithdrawnNCT05129423

Genentech, Inc.Chronic Spontaneous Urticaria

Start: 2022-07-31End: 2024-08-31Updated: 2022-11-18